Skip to main content
TipRanks
Go Ultimate75% OFF

Vext Science (VEXT) AI Stock Analysis

20 Followers
TSE:VEXT

Vext Science

(CNQX:VEXT)

Select Model
Rating:48Neutral
Price Target:CAD 0.18â–¼(-1.11% Downside)
Action:reiterated
Date:11/05/26

The overall score of 48 reflects a high-risk, turnaround situation. The most significant factor is the company's severely deteriorated financial performance, with collapsing margins and negative free cash flow. This is partially offset by a more constructive earnings call, which highlighted a credible strategic pivot to Ohio, significant margin recovery, and balance sheet repair efforts. Technical weakness and a negative P/E ratio further weigh on the score, indicating the market has yet to price in a successful turnaround.

Positive Factors
Margin ExpansionThe sharp improvement in gross and adjusted EBITDA margins indicates better operating execution and product economics. If sustained, stronger margins can improve earnings resilience, support internal reinvestment, and help the company absorb market pressure while scaling its operations.
Negative Factors
Revenue PressureThe top-line decline shows that operational improvements have not yet translated into broad revenue growth. Lower wholesale activity, particularly in Arizona, can limit scale benefits and make it harder for fixed operating costs to be absorbed across the business.

Vext Science (VEXT) vs. iShares MSCI Canada ETF (EWC)

-30%-20%-10%0%10%20%30%40%TSE:VEXT-29.41%EWC+20.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 32.20M
Dividend Yield
―
Average Volume (3M)
68.83K
Price to Earnings (P/E)
-1.6
Beta (1Y)
0.44
Revenue Growth
9.88%
EPS Growth
0.18%
Country
Canada
Employees
173
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Vext Science Business Overview & Revenue Model

Company Description

Vext Science, Inc. operates as a comprehensive enterprise within the United States' cannabis sector, encompassing agricultural technology, various services, and property management. The company is actively involved in cultivating, extracting, manufac...

Vext Science Earnings Call Summary

Earnings Call Date:Aug 20, 2026(Q2-2026)|% Change Since:-38.98%|Next Earnings Date:Jun 01, 2020
Earnings Call SentimentPositive

The call emphasized meaningful operational and margin improvements driven by Ohio execution and higher cultivation yields, alongside successful financing and balance sheet progress. These positives were balanced against a lower top line (driven by a planned Arizona cultivation wind-down), ongoing market weakness in Arizona, a significant uncertain tax liability, and modest reported operating cash flow due to deliberate inventory and payable timing. Management communicated a clear strategy to redeploy capital from Arizona to Ohio and to pay down debt, and they reported concrete near-term actions and improving trends.

Positive Updates

Improved Profitability and Margins
Gross profit rose to $6.7M from $4.9M a year ago and gross margin expanded to 55% (vs 36% prior year). Even before fair-value adjustments, margin improved to ~44% from ~39% year-over-year.

Negative Updates

Revenue Decline
Total revenue was $12.1M, down ~10% year-over-year; top-line decline driven primarily by a planned reduction in Arizona wholesale activity (wholesale revenue declined from $2.6M to $1.4M).

Company Guidance

Management guided to improved H2 performance as Arizona’s repositioning to a capital‑light retail/third‑party sourcing model completes, Ohio inventory converts to cash, Fairfield and the broader Ohio footprint scale, and capital is directed to strengthening the balance sheet, paying down debt, and funding Ohio growth; Q2 metrics cited as context include revenue of $12.1M (≈‑10% YoY, flat QoQ) with wholesale revenue down to $1.4M from $2.6M, gross profit $6.7M (vs $4.9M a year ago) and gross margin 55% (36% YoY; 44% before fair‑value adj.), adjusted EBITDA $3.4M (+22% QoQ from a corrected Q1 $2.8M) with a 28% adjusted EBITDA margin (vs 23%), net loss narrowed to $0.3M (vs $1.5M), cash from operations $1.2M (~10% cash‑flow margin) despite a deliberate $2M Ohio inventory build (expected to convert through H2; Ohio wholesale set a preliminary monthly record in July), cultivation yields now >100 g/plant (up ~68% over 2.5 years), Eloy property reclassified held‑for‑sale at $7.8M with proceeds earmarked to pay secured debt, cash ~$4.5M, net working capital improved from ‑$11.7M to ≈‑$0.9M (would be positive excluding an $11.7M uncertain tax position up from $8.1M), WPCU financing gross proceeds ≈$17M (used to refinance ~$10.5M WPCU debt, acquire Jackson, OH for $6M and fund expansion), and the East West Bank note maturity extended to Jan 2028.

Vext Science Financial Statement Overview

Summary

Financial performance is weak, driven by a severe collapse in profitability despite recent revenue growth. Gross margins have plummeted from 65.2% to 6.8% TTM, and the company has swung to a net loss. The balance sheet shows rising leverage with equity declining, and free cash flow has turned negative, indicating an unsustainable trajectory.

Income Statement

18Very Negative

Balance Sheet

42Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue52.74M52.27M36.00M34.81M35.41M37.24M
Gross Profit3.50M2.32M8.98M12.04M23.10M18.69M
EBITDA1.92M6.80M-2.02M16.77M15.29M12.82M
Net Income-11.60M-18.31M-22.44M4.40M10.92M4.99M
Balance Sheet
Total Assets118.95M120.31M136.97M149.56M120.52M83.70M
Cash, Cash Equivalents and Short-Term Investments5.58M5.07M4.62M8.72M5.93M6.47M
Total Debt38.61M34.97M39.52M38.60M38.15M14.10M
Total Liabilities69.97M65.04M61.23M54.58M48.60M24.31M
Stockholders Equity48.98M55.27M75.74M94.98M71.92M59.39M
Cash Flow
Free Cash Flow-1.18M8.29M1.82M1.69M-2.94M-7.10M
Operating Cash Flow8.37M11.92M3.29M4.42M5.92M11.68M
Investing Cash Flow-9.47M-5.76M-5.44M-4.82M-30.31M-27.10M
Financing Cash Flow3.07M-5.69M-1.95M3.19M23.86M20.14M

Vext Science Technical Analysis

Technical Analysis SentimentNegative
Last Price0.18

Price Trends

50DMA0.24Negative
100DMA0.25Negative
200DMA0.26Negative

Market Momentum

MACD-0.01Positive
RSI34.21Neutral
STOCH27.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.24, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.21 is Neutral, neither overbought nor oversold. The STOCH value of 27.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.

Vext Science Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:VEXT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS57NeutralCAD 27.77M-10.00-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VEXTTSE:VEXT48NeutralCAD 44.59M-1.59-31.34%―9.88%0.18%
TSE:LEEFTSE:LEEF45NeutralCAD 67.22M-1.73206.83%―――
TSE:AVCNTSE:AVCN42NeutralCAD 13.44M-4.54-65.40%―-3.32%-34.15%
TSE:CWEBTSE:CWEB42NeutralCAD 66.59M-0.89-139.31%―-9.90%-35.35%
TSE:PLTHTSE:PLTH39UnderperformCAD 40.24M-1.11-59.17%―-15.64%71.65%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%800%TSE:VEXTTSE:LEEFTSE:CWEBTSE:LABSTSE:PLTHTSE:AVCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:VEXT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:VEXTVext Science0.18-0.06-25.00%
TSE:LEEFLeef Brands Inc0.22-0.02-10.20%
TSE:CWEBCharlotte's Web Holdings (OTC)0.240.1075.00%
TSE:LABSMedipharm Labs (Otc)0.070.000.00%
TSE:PLTHPlanet 13 Holdings, Inc.0.12-0.10-44.19%
TSE:AVCNAvicanna Inc0.10-0.14-59.18%

Vext Science Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance

Vext Reports Record Revenue and Stronger Operating Cash Flow

Positive
Nov 3, 2026

Vext Science is a U.S.-based specialty retailer of regulated cannabis products, including flower and packaged goods, operating in Ohio and Arizona. Third-quarter revenue reached a record $14.9 million, up 23% sequentially and 18% year over year, whil...

Business Operations and Strategy

Vext Science Reaches Ohio Dispensary Cap With Amelia License

Positive
Oct 29, 2026

Vext Science has secured a provisional dual-use license for its eighth Ohio dispensary in Amelia, reaching the maximum number of stores allowed for a single operator in the state. The new location, paired with the recently opened Fairfield dispensary...

Business Operations and StrategyFinancial Disclosures

Vext Science Sets November 3 Date for Q3 2026 Results

Neutral
Oct 29, 2026

Vext Science, Inc., a U.S.-based specialty cannabis retailer operating in Ohio and Arizona, runs a largely vertically integrated model by owning its dispensaries, most underlying real estate, and supplying shelves from its own cultivation and manufac...

Business Operations and StrategyRegulatory Filings and Compliance

Vext Science Regains Full Sales Clearance for Vapen Products in Ohio

Positive
Oct 15, 2026

Vext Science, Inc., a specialty cannabis retailer with vertically integrated operations in Ohio and Arizona, has built a model around owning its dispensaries and much of its real estate while supplying stores from both internal production and select...

Business Operations and StrategyPrivate Placements and Financing

Vext Reopens Ohio Dispensary and Eases 2026 Debt Maturity Burden

Positive
Sep 17, 2026

Vext Science has reopened its Herbal Wellness Center dispensary in Jackson, Ohio after receiving authorization from the Ohio Division of Cannabis Control, restoring service to patients and customers in the area. The company emphasized its commitment...

Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance

Vext Science Shuts Jackson, Ohio Dispensary Amid Health-Event Probe

Negative
Sep 4, 2026

Vext Science has voluntarily closed its Herbal Wellness Center dispensary in Jackson, Ohio at the request of the Ohio Division of Cannabis Control, which is investigating two serious adverse health events possibly involving products purchased at that...

Business Operations and StrategyFinancial Disclosures

Vext Science Boosts Q2 Profitability as Ohio Growth Offsets Arizona Exit

Positive
Aug 20, 2026

Vext Science reported second-quarter 2026 revenue of $12.1 million, in line with the prior quarter, as growth in Ohio retail offset the planned wind-down of Arizona cultivation and wholesale operations. Adjusted EBITDA rose 22% sequentially to $3.4 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026